Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Invest New Drugs. 2016 Nov 8;35(1):87–94. doi: 10.1007/s10637-016-0403-2

Table 2.

Treatment-related adverse events at least possibly related to orteronel.

Adverse Event Grade 1 n (%) Grade 2 n (%) Grade 3 n (%)
Fatigue 1 (12%)
Nausea 3 (37%) 1 (12%)
Chills 1 (12%)
Hot Flashes 2 (25%)
Skin changes 1 (12%)
Headache 1 (12%)
Hirsuitism 1 (12%)
Bone Pain 2 (25%) 1 (12%)
Myalgia 2 (25%)
Hypertension 2 (25%)
Hypokalemia 2 (25%)
Hyperglycemia 1 (12%)
Hypoglycemia 1 (12%)
Hypocalcaemia 1 (12%)
Hypophosphatemia 1 (12%)
QT prolongation 1 (12%)
AST elevation 2 (25%)
Lymphopenia 1 (12%)
Creatinine elevation 1 (12%)